Switch therapy of the association of ampicillin and sulbactam in a hospital complex in southern Brazil
Keywords:anti-bacterial agents, antimicrobial stewardship, pharmacy service, hospital
Objective: To identify the frequency of pharmaceutical interventions performed and accepted by the physicians and the cost savings generated by the switch therapy of the association of ampicillin and sulbactam to the association of amoxicillin and potassium clavulanate in adult patients in a hospital complex. Methods: Observational cross-sectional study, based on the assessment of adult patients in intravenous use of the association of ampicillin and sulbactam for more than three days, from April to June 2021. Sampling was done for convenience. Interventions suggesting the change to the tablet of the association of amoxicillin and potassium clavulanate were performed through standard alert and evolution in the electronic health record of eligible patients. Acceptance was verified by followup of the new prescription. If not accepted, a new intervention was performed in 48 hours. Cost savings were calculated based on the average cost of medicines and medical supplies, available on the institution’s computerized system. The collected data were analyzed using descriptive statistics. Results: A total of 322 patients were evaluable, of which 174 (54,0%) were considered eligible for the switch therapy. A total of 226 pharmaceutical interventions were performed, in which 14 (6,2%) were accepted by the physicians, generating savings of US$912,56. Conclusions: Pharmaceutical interventions recommending the switch therapy of the association of ampicillin and sulbactam had low adherence by the physicians, but, despite this, they presented a significant potential for cost savings. To obtain better results, it is necessary to promote the education of the clinical staff and improve communication between pharmacists and physicians.
How to Cite
Copyright (c) 2021 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.